Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Rapid Communication

The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society

Hiroyuki Nagase a,*, Yoshihiro Nishimura b, Hisako Matsumoto c, Naoya Sugimoto a, Takashi Iwanaga c, Akiko Sano c, Satoshi Konno d, Nobuyuki Hizawa e, Koichiro Asano f, Takahiko Horiguchi g, Akihito Yokoyama h, The Japanese Respiratory Society, Scientific Assembly for Allergy, Immunology, and Inflammation

a Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan
b Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
c Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan
d Department of Respiratory Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan
e Department of Pulmonary Medicine, University of Tsukuba, Tsukuba, Japan
f Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan
g Department of Respiratory Medicine and Clinical Allergy, Fujita Health University, Aichi, Japan
h Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kochi, Japan

A R T I C L E  I N F O

Article history:
Received 15 April 2021
Received in revised form 21 May 2021
Accepted 14 June 2021
Available online 15 July 2021

A B S T R A C T

There is a concern that persons with underlying respiratory disease may have increased susceptibility to COVID-19 and/or increased severity/mortality if infected. However, information regarding such patients during the first wave of the epidemic is lacking in Japan. We surveyed chest physicians nationwide, and collected anonymous data concerning 1444 patients.

Among COVID-19 patients, the prevalence of asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases (ILD) was 3.4%, 4.8%, and 1.5%, respectively. Among COVID-19 patients with these 3 comorbidities, exacerbation of the comorbidity occurred in 12.2%, 18.8%, and 36.4%, respectively, and mortality (6.2% overall) was 4.1%, 13.0%, and 31.8%, respectively.

Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ILD, interstitial lung disease; Japanese Respiratory Society, JRS; LPV/r, lopinavir/ritonavir; MV, mechanical ventilation; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

* Corresponding author. Division of Respiratory Medicine and Allergology, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
E-mail address: nagaseh@med.teikyo-u.ac.jp (H. Nagase).
https://doi.org/10.1016/j.resinv.2021.06.008
2212-5345/© 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), continues to spread worldwide. In Japan, a total of 473,045 cases with 9182 deaths were confirmed as of April 2, 2021 [1] and a fourth wave of the pandemic is in progress. Recently, the prevalence of comorbid respiratory diseases among patients with COVID-19, and the effect of such respiratory comorbidities on the severity of COVID-19, has received increasing attention. Viral infection can trigger exacerbation of underlying respiratory conditions, so the risk of mortality in SARS-CoV-2 infection among people with such comorbidities is likely higher.

The aim of our study was to investigate the prevalence of comorbid respiratory diseases among patients with COVID-19 and mortality during the first wave of pandemic in Japan through a national survey of chest physicians using an online questionnaire.

The study was conducted from 27 May to 17 June 2020, during the first wave of the pandemic in Japan. Japan’s number of newly diagnosed COVID-19 patients reached a peak of 708 on April 10, then fell to 22 by June 8. Responsible chest physicians of the country’s 904 health institutions certified by the Japanese Respiratory Society (JRS) were asked to participate. The questionnaire concerned patients with COVID-19 and included questions regarding: prevalence and exacerbation of underlying respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and lung cancer; mortality; the use of selected drugs; mechanical ventilation (MV); and extracorporeal membrane oxygenation (ECMO). Aggregated data responses were fed into an online data collection form. The requirement for ethical approval was waived by the ethical review board of Kobe University, due to the anonymous nature of the data collected.

Of the 171 responding institutions (18.9%), 111 institutions (64.9%) treated COVID-19 patients, accounting for a total of 1444 patients. The Tokyo Metropolitan area accounted for 21.5% of the patients, and Tokyo Metropolitan area plus Kanto and Kinki districts together accounted for 66.0% of the patients (Table 1). At the time, Japan’s COVID-19 case count was 17,645 (June 17), and the proportion from Tokyo, Kanto, and Kinki regions was 73.4% [1], so our survey covered 8.2% of the nationwide number of patients and reflected the actual geographic distribution of cases.

According to our data, the prevalence of asthma, COPD, and ILD among COVID-19 patients was 3.4%, 4.8%, and 1.5%, respectively (Table 2). The incidence of physician-reported exacerbation or worsening of comorbid respiratory disease was 12.2% in the case of asthma, and 36.4% in the case of ILD.

Overall mortality among COVID-19 patients was 6.2% (Table 2). Compared to patients without respiratory comorbidity (5.1% mortality), mortality was lower in patients with asthma (4.1%), and higher in patients with COPD (13.0%), ILD (31.8%), and lung cancer (38.5%).

The most frequently prescribed drug was favipiravir (35.5%), followed by ciclesonide (24.1%), whereas only 8.5% of the patients were treated with systemic corticosteroids (Fig. 1). Patients with comorbid respiratory diseases were more frequently treated with favipiravir or ciclesonide than those without respiratory comorbidity (Table 3). The same was true for treatment with systemic corticosteroids, with the exception of patients with asthma, for whom systemic corticosteroids were prescribed less frequently (4.1%) compared to patients without respiratory comorbidity (7.2%).

The proportion of patients placed on MV was higher among patients with COPD or ILD than in patients without respiratory comorbidity (Table 3). ECMO was not used in patients with COPD, ILD, and lung cancer.

In the current study, the mortality in patients without comorbid respiratory disease (5.1%, Table 2) was comparable to the reported overall mortality in Japan (5.3%) at the time of investigation [1]. However, total mortality in patients with respiratory diseases other than asthma was 20.2% (21 deaths from 104 patients), suggesting the paramount importance of prevention of COVID-19 for such patients.

Our data showed a prevalence of asthma among patients with COVID-19 (3.4%) that was lower than the general prevalence of asthma among adults in other countries [2] and in Japan (10.4%) [3], suggesting a lower susceptibility to COVID-19 in persons with asthma. Previous reports have also shown that severity of COVID-19 is not increased by comorbid asthma [4]; the risk was slightly higher for a subgroup of patients with non-allergic phenotype or recent systemic corticosteroid use, but the extent was smaller compared to obesity.

| Region               | Institutions (n) | Patients (n) | Patients (%) |
|----------------------|------------------|--------------|--------------|
| Hokkaido             | 4                | 62           | 4.3%         |
| Tohoku               | 5                | 64           | 4.4%         |
| Kanto (other than Tokyo) | 27              | 320          | 22.2%        |
| Tokyo Metropolitan   | 18               | 310          | 21.5%        |
| Tokai                | 12               | 90           | 6.2%         |
| Hokuriku             | 5                | 149          | 10.3%        |
| Kinki                | 20               | 322          | 22.3%        |
| Chugoku/Shikoku      | 11               | 49           | 3.4%         |
| Kyushu               | 9                | 78           | 5.4%         |
| **Total**            | **111**          | **1444**     | **100.0%**   |
or diabetes [4]. In line with the report, the mortality of patients with asthma (4.1%) did not exceed that of patients without respiratory comorbidity (5.1%) in this study (Table 2). Although the leading cause of asthma exacerbation is infection by viruses, including rhinovirus [3]. As for SARS-CoV-2, the incidence of physician-reported exacerbation of asthma was limited to 12.2% and systemic corticosteroids were prescribed only for 4.1% patients in this study. Findings, both previous and current, concerning low susceptibility or risk for severe COVID-19 in asthma, can be partly explained by the decrease in expression of ACE2 receptor due to inhaled corticosteroids [5] or type 2 cytokines, including IL-13 [6].

Concerning COPD, the susceptibility to COVID-19 is controversial, and it is difficult to infer the extent of susceptibility from our results due to the lack of information regarding age. However, comorbid COPD has been established as a risk factor for severity of COVID-19 [7], and the elevated mortality in our survey (13.0%) is consistent with that. Although 11 patients with COPD were on MV (Table 3), successful weaning was apparently possible in some patients because the number of deaths was 9. Further investigation is required to establish the prediction factor to determine the indication for MV.

Previous reports have revealed high mortality in patients with ILD [8]. The mortality in our study (31.8%) was indeed higher than the reported mortality among COVID-19 patients aged >80 years (28.3%), which is the highest mortality age bracket [1]. Although the number of deaths was 7, only 4 patients were on MV and none of the patients were on ECMO (Table 3), suggesting the estimation of poor prognosis by the physicians involved.

During the first wave in Japan, favipiravir followed by ciclesonide were frequently prescribed, more often to patients with respiratory diseases (Table 3). This might have been due to the higher severity of COVID-19 in patients with respiratory diseases, suggested by high mortality in patients with COPD, ILD, and lung cancer. Since the first wave, there has important progress in treatment for COVID-19, such as the establishment of indication of systemic steroids, the limited efficacy of ciclesonide for mild cases, and the approval of remdesivir in Japan [9]. These advancements may further improve the

### Table 2 – Prevalence and exacerbation of comorbid respiratory disease, and mortality among COVID-19 patients.

| Prevalence of comorbid respiratory disease | Asthma | COPD | ILD | Lung cancer | No respiratory disease | Total |
|------------------------------------------|--------|------|-----|-------------|------------------------|-------|
| N                                        | 49     | 69   | 22  | 13          | 1291                   | 1444  |
| %                                        | 3.4%   | 4.8% | 1.5%| 0.9%        | 89.4%                  | 100%  |

| Exacerbation | Asthma | COPD | ILD | Lung cancer | No respiratory disease | Total |
|--------------|--------|------|-----|-------------|------------------------|-------|
| N            | 6      | 13   | 8   | NA          | NA                     | NA    |
| %            | 12.2%  | 18.8%| 36.4%| NA          | NA                     | NA    |

| Death**      | Asthma | COPD | ILD | Lung cancer | No respiratory disease | Total |
|--------------|--------|------|-----|-------------|------------------------|-------|
| N            | 2      | 9    | 7   | 5           | 66                     | 89    |
| %            | 4.1%   | 13.0%| 31.8%| 38.5%       | 5.1%                   | 6.2%  |

**p < 0.01, Pearson’s Chi-square test.
COPD, Chronic Obstructive Lung Disease; ILD, Interstitial lung disease.

### Table 3 – Treatment of COVID-19 patients with comorbid respiratory diseases.

| Asthma | COPD | ILD | Lung cancer | No respiratory disease | Total |
|--------|------|-----|-------------|------------------------|-------|
| Patients | 49   | 69  | 22          | 13                     | 1291  | 1444  |
| Systemic Steroids** | N 2 | 17  | 7           | 3                      | 93    | 122   |
| %        | 4.1% | 24.6%| 31.8%       | 23.1%                  | 7.2%  | 8.5%  |
| Ciclesonide** | N 29 | 30   | 13          | 12                     | 264   | 348   |
| %        | 59.2%| 43.5%| 59.1%       | 92.3%                  | 20.5% | 24.1% |
| Favipiravir** | N 21 | 36  | 11          | 8                      | 437   | 513   |
| %        | 42.9%| 52.2%| 50.0%       | 61.5%                  | 33.9% | 35.5% |
| Mechanical Ventilation** | N 2  | 11  | 4           | 4                      | 94    | 115   |
| %        | 4.1% | 15.9%| 18.2%       | 30.8%                  | 7.3%  | 8.0%  |
| Extracorporeal membrane oxygenation** | N 2 | 0   | 0           | 0                      | 18    | 20    |
| %        | 4.1% |      |             |                        | 1.4%  | 1.4%  |

**p < 0.01, Pearson’s Chi-square test.
COPD, Chronic Obstructive Lung Disease; ILD, Interstitial lung disease.
prognosis of patients with COVID-19 and the investigation of mortality in following waves is required.

The limitations of our study include the lack of data about age, gender, baseline treatment, COVID-19 severity, and comorbidities other than respiratory diseases. The above-mentioned data were unavailable due to the data collection approach and reliance on physician responses. The coverage of institution was 18.8%, and the number of COVID-19 patients diagnosed with ILD and lung cancer was limited, which merits further investigation into each specific respiratory disease.

In conclusion, the prevalence of asthma among COVID-19 patients was low compared to the general population, co-morbidity with asthma was not related to COVID-19 mortality, and ILD was a comorbid respiratory disease associated with a particularly high COVID-19 mortality. These findings will help to establish an appropriate strategy for prevention and treatment for COVID-19 in patients with comorbid respiratory diseases.

**Funding sources**

None.

**Conflict of Interest**

The authors have no conflicts of interest.

**Acknowledgments**

The authors gratefully acknowledge JRS members participated in the survey. We would also like to thank Ms. Yurie Ogawa and Ms. Nozomi Hakamada in JRS for their outstanding secretarial assistance with the online survey and Enago (www.enago.com) for the English language review.

**REFERENCES**

[1] The Ministry of Health Labour and Welfare of Japan. Current situation in Japan. 2021. https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou_00006.html#1-1.

[2] Mendes NF, Jara CP, Mansour E, Araújo EP, Velloso LA. Asthma and COVID-19: a systematic review. Allergy Asthma Clin Immunol 2021;17:5.

[3] Nakamura Y, Tamaoki J, Nagase H, Yamaguchi M, Horiguchi T, Hozawa S, et al. Japanese guidelines for adult asthma 2020. Allergol Int 2020;69:519–48.

[4] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430–6.

[5] Peters MC, Sajuthi S, Deford F, Christenson S, Rios CL, Montgomery MT, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020;202:83–90.

[6] Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 2020;146:80–8.

[7] Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol 2020;92:1915–21.

[8] Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med 2020;202:1656–65.

[9] The Ministry of Health Labour and Welfare of Japan. Clinical management of patients with COVID-19. version 4.2 (in Japanese). 2021. https://www.mhlw.go.jp/content/000742297.pdf.